{"title":"血液制品对免疫功能不全患者破伤风抗体浓度变化的影响。","authors":"M Pietsch, S Töre, K H Schütt","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Collecting of data for immunoprophylaxis of tetanus in immunodeficient patients via administration of blood products.</p><p><strong>Design: </strong>Prospective single case studies.</p><p><strong>Setting: </strong>Clinical therapy in a department of hematology with continuous determination of tetanus antibody concentrations in patients' sera and administered blood products with an enzyme immunoassay.</p><p><strong>Patients: </strong>3 patients with acute myeloid leukemia (FAB classifications M1, M3, M4).</p><p><strong>Interventions: </strong>Regular administration of blood products due to clinical therapy.</p><p><strong>Results: </strong>After administration of about 4,000 IU tetanus antitoxin i.v., serum concentration is increasing by 1 IU/ml. Half life in serum amounts to 7 days. Protection lasts therefore up to 6 weeks.</p><p><strong>Conclusions: </strong>Immunodeficient patients may receive a medium-term effective protection against tetanus after selection of suitable blood products. This method is interesting also for prophylaxis of postoperative tetanus in immunocompetent patients.</p>","PeriodicalId":13632,"journal":{"name":"Infusionstherapie und Transfusionsmedizin","volume":"23 1","pages":"25-8"},"PeriodicalIF":0.0000,"publicationDate":"1996-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Effect of administration of blood products on the course of tetanus antibody concentration in immuno-incompetent patients].\",\"authors\":\"M Pietsch, S Töre, K H Schütt\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Collecting of data for immunoprophylaxis of tetanus in immunodeficient patients via administration of blood products.</p><p><strong>Design: </strong>Prospective single case studies.</p><p><strong>Setting: </strong>Clinical therapy in a department of hematology with continuous determination of tetanus antibody concentrations in patients' sera and administered blood products with an enzyme immunoassay.</p><p><strong>Patients: </strong>3 patients with acute myeloid leukemia (FAB classifications M1, M3, M4).</p><p><strong>Interventions: </strong>Regular administration of blood products due to clinical therapy.</p><p><strong>Results: </strong>After administration of about 4,000 IU tetanus antitoxin i.v., serum concentration is increasing by 1 IU/ml. Half life in serum amounts to 7 days. Protection lasts therefore up to 6 weeks.</p><p><strong>Conclusions: </strong>Immunodeficient patients may receive a medium-term effective protection against tetanus after selection of suitable blood products. This method is interesting also for prophylaxis of postoperative tetanus in immunocompetent patients.</p>\",\"PeriodicalId\":13632,\"journal\":{\"name\":\"Infusionstherapie und Transfusionsmedizin\",\"volume\":\"23 1\",\"pages\":\"25-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1996-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infusionstherapie und Transfusionsmedizin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infusionstherapie und Transfusionsmedizin","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[Effect of administration of blood products on the course of tetanus antibody concentration in immuno-incompetent patients].
Objective: Collecting of data for immunoprophylaxis of tetanus in immunodeficient patients via administration of blood products.
Design: Prospective single case studies.
Setting: Clinical therapy in a department of hematology with continuous determination of tetanus antibody concentrations in patients' sera and administered blood products with an enzyme immunoassay.
Interventions: Regular administration of blood products due to clinical therapy.
Results: After administration of about 4,000 IU tetanus antitoxin i.v., serum concentration is increasing by 1 IU/ml. Half life in serum amounts to 7 days. Protection lasts therefore up to 6 weeks.
Conclusions: Immunodeficient patients may receive a medium-term effective protection against tetanus after selection of suitable blood products. This method is interesting also for prophylaxis of postoperative tetanus in immunocompetent patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
